Paricalcitol Generics

Form: Capsules and Injection

Strength: Capsules:1mcg, 2mcg, 4 mcg & Injection: 2mcg/mL , 5mcg/mL

Reference Brands: Zemplar®(US &EU)

Category: Nephrology

Paricalcitol, marketed as Zemplar®, is a selective vitamin D receptor activator used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD), both on dialysis (stage 5) and in pre-dialysis stages (3–4). It effectively lowers parathyroid hormone (PTH) levels while minimizing the risk of hypercalcemia and hyperphosphatemia. Available as oral capsules (1 mcg, 2 mcg, 4 mcg) and IV injection (2 mcg/mL, 5 mcg/mL), Paricalcitol is approved in both the US (FDA) and EU (EMA). It is a key therapeutic in nephrology and an excellent B2B opportunity for licensing, distribution, and hospital-based partnerships in regulated markets.